Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SPR | P35270 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711904 | 0.89 | CHRM1 (0.54) | CHRM1SPRLIPEKMT2AMEN1 | |
| SCHEMBL18711931 | 0.81 | KMT2A (0.73) | KMT2AMEN1PKMALDH1A1 | |
| SCHEMBL18702176 | 0.80 | PKM (0.58) | KMT2AMEN1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL28663136 | 0.80 | TSHR (0.62) | CHRM1LIPEKMT2AMEN1KDM2B | |
| SCHEMBL31684033 | 0.80 | TSHR (0.62) | CHRM1LIPEKMT2AMEN1KDM2B | |
| SCHEMBL18702188 | 0.80 | EPHX2 (0.53) | LIPEKMT2AMEN1PKMSMN1; SMN2 | |
| SCHEMBL18701958 | 0.79 | EPHX2 (0.49) | KMT2AMEN1ALDH1A1CNR1SMN1; SMN2 | |
| SCHEMBL18701981 | 0.79 | CNR1 (0.53) | KMT2AMEN1ALDH1A1CNR1 | |
| SCHEMBL27848170 | 0.79 | MEN1 (0.49) | CHRM1SPRLIPEKMT2AMEN1 | |
| SCHEMBL25145574 | 0.78 | KMT2A (0.48) | CHRM1LIPEKMT2AMEN1KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | CHRM1 3106/4885SPR 1/4885LIPE 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.